AIM (AIM ImmunoTech) Mohanram G-Score: 4 (As of Mar. 2026) — 33% Above Median


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.31
GF Value $2.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Mohanram G-Score?

AIM ImmunoTech AIM -12.18% 33 Mohanram G-Score is 4 as of Mar. 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

AIM ImmunoTech has an G-score of 4.

The historical rank and industry rank for AIM ImmunoTech's Mohanram G-Score or its related term are showing as below:

AIM' s Mohanram G-Score Range Over the Past 10 Years
Min: 0   Med: 3   Max: 6
Current: 4

During the past 13 years, the highest Piotroski G-score of AIM ImmunoTech was 6. The lowest was 0. And the median was 3.

AIM ImmunoTech  (AMEX:AIM) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


AIM ImmunoTech Mohanram G-Score Related Terms


AIM ImmunoTech Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Mohanram G-Score Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 3.00 5.00 4.00

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 3.00 4.00 4.00

AIM vs BGMS, FBLG, CLGN: Mohanram G-Score Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech Mohanram G-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Mohanram G-Score falls into.


AIM
33GF Score
AIM ImmunoTech Inc AIM
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

AIM ImmunoTech has an G-score of 4.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 4 mean?
AIM ImmunoTech (AIM) has a Mohanram G-Score of 4 as of Mar. 2026. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on AIM ImmunoTech and its competitors. This is 33% above median its historical median of 3.00.
Is AIM ImmunoTech's Mohanram G-Score too high?
AIM ImmunoTech's current Mohanram G-Score of 4 is 33% above median its 10-year median of 3.00. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Mohanram G-Score compare to BGMS and FBLG?
AIM ImmunoTech's Mohanram G-Score of 4 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Biotechnology company?
A good Mohanram G-Score depends on the Biotechnology industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Mohanram G-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current Mohanram G-Score is 4, which is 33% above median its 10-year median of 3.00. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Mohanram G-Score is 4 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Mohanram G-Score: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price
$2.69
GF Value